Skip to main content
NeuronFeed

immunitoAI vs Pathos AI

Which Drug Discovery AI tool is better in 2026?

immunitoAI

$6.1M

Pathos AI

$467M

Side-by-side

Verdict

Pathos AI is the more established option (raised $467M); pricing is comparable on both sides.

Metric immunitoAI Pathos AI
Taglinei
Foundedi 2020🏆 2022
HQi
Employeesi 11-50 11-50
Neuron scorei 62 72🏆
Total fundingi $6.1M $467M🏆
Latest roundi Series A Series D · May 2025
Valuationi $1.6B🏆
Cheapest paid plani Pricing not disclosed Pricing not disclosed
Free plani
Free triali
Top tier pricei Pricing not disclosed Pricing not disclosed
Pricing summaryi Free Free
Categoriesi

Capability matrix

Developer-facing capabilities and access signals for immunitoAI and Pathos AI.

Capability immunitoAI Pathos AI
MCP support
Public API
Webhooks
OAuth 2.0
SDK languages
Free plan
Free trial
Verified
Active deal

🟢 Strengths of immunitoAI

  • More mature (2020)

🔵 Strengths of Pathos AI

  • Has raised more capital ($467M vs $6.1M)
  • Higher Neuron score (72 vs 62)
  • Newer company (2022)

Which should you choose?

Choose Pathos AI if price matters most — it starts at Free, which is friendlier for teams watching burn. Both Drug Discovery tools ship core features, so the cost delta often decides it for small teams and solo operators.

Choose Pathos AI if you want the most established option — it has raised $467M, suggesting more runway for enterprise features, support, and long-term roadmap. For mission-critical workflows or larger teams, that stability often outweighs a lower monthly price.

Frequently asked questions

immunitoAI vs Pathos AI — which is better?

It depends on your priority. immunitoAI is the leaner option; Pathos AI has broader feature depth. See the side-by-side table above.

Is immunitoAI cheaper than Pathos AI?

No — Pathos AI's cheapest paid plan is Free, while immunitoAI's is Free.

Do immunitoAI and Pathos AI offer free plans?

immunitoAI: Yes, has a free plan. Pathos AI: Yes, has a free plan.

Contextual paths to related AI startups, deals and rankings.